{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:50:17Z","timestamp":1768902617426,"version":"3.49.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-143270"],"award-info":[{"award-number":["FDN-143270"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are limited data on the real-world effectiveness of direct-acting antiviral (DAA) treatment in patients coinfected with hepatitis C virus (HCV) and HIV\u2014a population with complex challenges including ongoing substance use, cirrhosis, and other comorbidities. We assessed how patient characteristics and the appropriateness of HCV regimen selection according to guidelines affect treatment outcomes in coinfected patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included all patients who initiated DAA treatment between November 2013 and July 2017 in the Canadian Co-Infection Cohort. Sustained virologic response (SVR) was defined as an undetectable HCV RNA measured between 10 and 18 weeks post-treatment. We defined treatment failure as virologic failure, relapse, or death without achieving SVR. Bayesian logistic regression was used to estimate the posterior odds ratios (ORs) associated with patient demographic, clinical, and treatment-related risk factors for treatment failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred ninety-five patients initiated DAAs; 31% were treatment-experienced, 29% cirrhotic, and 80% HCV genotype 1. Overall, 92% achieved SVR (263 of 286, 9 unknown), with the highest rates in females (97%) and lowest in cirrhotics (88%) and high-frequency injection drug users (89%). Many patients (38%) were prescribed regimens that were outside current clinical guidelines. This did not appreciably increase the risk of treatment failure\u2014particularly in patients with genotype 1 (prior odds ratio [OR], 1.5; 95% credible interval [CrI], 0.38\u20136.0; posterior OR, 1.0; 95% CrI, 0.40\u20132.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DAAs were more effective than anticipated in a diverse, real-world coinfected cohort, despite the use of off-label, less efficacious regimens. High-frequency injection drug use and cirrhosis were associated with an increased risk of failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofz055","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T22:54:14Z","timestamp":1550098454000},"source":"Crossref","is-referenced-by-count":13,"title":["Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV\u2013Coinfected Patients in Clinical Care"],"prefix":"10.1093","volume":"6","author":[{"given":"Carmine","family":"Rossi","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, Glen Site, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, Glen Site, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Martel-Laferri\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Walmsley","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto, Toronto, Canada"},{"name":"CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[{"name":"Regina Qu\u2019Appelle Health Region, Regina, Saskatchewan, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M John","family":"Gill","sequence":"additional","affiliation":[{"name":"Southern Alberta HIV Clinic, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina B","family":"Klein","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, Glen Site, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Canadian Co-Infection Cohort Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shariq","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neora","family":"Pick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Rachlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Sadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Sanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Sandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Tyndall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Louise","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"2020081003472495600_CIT0001","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"2020081003472495600_CIT0002","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.29642","article-title":"Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population","volume":"67","author":"Sikavi","year":"2018","journal-title":"Hepatology"},{"key":"2020081003472495600_CIT0003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study","volume":"2","author":"Razavi","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020081003472495600_CIT0004","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/jis928","article-title":"Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV\/HIV coinfection: action required at the system, provider, and patient levels","volume":"207","author":"Grebely","year":"2013","journal-title":"J Infect Dis"},{"key":"2020081003472495600_CIT0005","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2020081003472495600_CIT0006","doi-asserted-by":"crossref","first-page":"e25062","DOI":"10.1002\/jia2.25062","article-title":"Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?","volume":"21","author":"Martin","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2020081003472495600_CIT0007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020081003472495600_CIT0008","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/COH.0000000000000183","article-title":"Epidemiology of hepatitis C virus in HIV-infected patients","volume":"10","author":"Peters","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"2020081003472495600_CIT0009","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world?","volume":"62","author":"Saeed","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0010","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkw203","article-title":"High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV\/HCV-coinfected patients: a real-world perspective","volume":"71","author":"Hawkins","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081003472495600_CIT0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","article-title":"Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort","volume":"67","author":"Piroth","year":"2017","journal-title":"J Hepatol"},{"key":"2020081003472495600_CIT0012","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0013","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.29308","article-title":"High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center","volume":"66","author":"Falade-Nwulia","year":"2017","journal-title":"Hepatology"},{"key":"2020081003472495600_CIT0014","doi-asserted-by":"crossref","first-page":"e0183609","DOI":"10.1371\/journal.pone.0183609","article-title":"A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV\/HCV infections in British Columbia","volume":"12","author":"Butt","year":"2017","journal-title":"PLoS One"},{"key":"2020081003472495600_CIT0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/ciw219","article-title":"Management of hepatitis C\/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy","volume":"63","author":"Wyles","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0016","doi-asserted-by":"crossref","first-page":"(X):XXX\u2013XX","DOI":"10.1093\/ofid\/ofx158","article-title":"Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus\/human immunodeficiency virus coinfection","volume":"4","author":"Boesecke","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020081003472495600_CIT0017","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ije\/dyp297","article-title":"Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study","volume":"39","author":"Klein","year":"2010","journal-title":"Int J Epidemiol"},{"key":"2020081003472495600_CIT0018","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.3748\/wjg.15.4993","article-title":"Hepatitis C comorbidities affecting the course and response to therapy","volume":"15","author":"El-Zayadi","year":"2009","journal-title":"World J Gastroenterol"},{"key":"2020081003472495600_CIT0019","volume-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.","author":"Infectious Disease Society of America (IDSA)","year":"2017"},{"key":"2020081003472495600_CIT0020","first-page":"40","article-title":"Heroin and cocaine co-use in a group of injection drug users in Montr\u00e9al","volume":"29","author":"Leri","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"2020081003472495600_CIT0021","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"key":"2020081003472495600_CIT0022","doi-asserted-by":"crossref","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"key":"2020081003472495600_CIT0023","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ije\/dyi312","article-title":"Bayesian perspectives for epidemiological research: I. Foundations and basic methods","volume":"35","author":"Greenland","year":"2006","journal-title":"Int J Epidemiol"},{"key":"2020081003472495600_CIT0024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/ije\/dyl289","article-title":"Bayesian perspectives for epidemiological research. II. Regression analysis","volume":"36","author":"Greenland","year":"2007","journal-title":"Int J Epidemiol"},{"key":"2020081003472495600_CIT0025","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1002\/sim.2788","article-title":"Prior data for non-normal priors","volume":"26","author":"Greenland","year":"2007","journal-title":"Stat Med"},{"key":"2020081003472495600_CIT0026","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cix126","article-title":"Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV","volume":"64","author":"Young","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12879-016-2106-x","article-title":"The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease","volume":"17","author":"Young","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2020081003472495600_CIT0028","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/hep.29005","article-title":"Eight weeks of ledipasvir\/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection","volume":"65","author":"Kowdley","year":"2017","journal-title":"Hepatology"},{"key":"2020081003472495600_CIT0029","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus\/HCV-coinfected subjects in real-world practice: Madrid Coinfection Registry findings","volume":"68","author":"Berenguer","year":"2018","journal-title":"Hepatology"},{"key":"2020081003472495600_CIT0030","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciw567","article-title":"Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German Hepatitis C Cohort (GECCO-01)","volume":"63","author":"Ingiliz","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0031","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"2020081003472495600_CIT0032","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/liv.13626","article-title":"Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in \u201cspecial populations.\u201d","volume":"38","author":"Pol","year":"2018","journal-title":"Liver Int"},{"key":"2020081003472495600_CIT0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: results in real life","volume":"38","author":"H\u00e9zode","year":"2018","journal-title":"Liver Int"},{"key":"2020081003472495600_CIT0034","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/COH.0000000000000292","article-title":"Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection","volume":"11","author":"Klein","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2020081003472495600_CIT0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/jhep.2002.35065","article-title":"Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users","volume":"36","author":"Miller","year":"2002","journal-title":"Hepatology"},{"key":"2020081003472495600_CIT0036","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.drugalcdep.2015.04.005","article-title":"Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada","volume":"152","author":"Cunningham","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2020081003472495600_CIT0037","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0038","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3117","article-title":"Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients","volume":"22","author":"Backus","year":"2017","journal-title":"Antivir Ther"},{"key":"2020081003472495600_CIT0039","article-title":"Non-adherence is the most important risk factor for ledipasvir\/sofosbuvir HCV treatment failure in the real world (conference abstract)","author":"Sarpel"},{"key":"2020081003472495600_CIT0040","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","article-title":"Natural history and management of hepatitis C: does sex play a role?","volume":"209","author":"Baden","year":"2014","journal-title":"J Infect Dis"},{"key":"2020081003472495600_CIT0041","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1086\/510682","article-title":"Cirrhosis is associated with low CD4+ T cell counts: implications for HIV-infected patients with liver disease","volume":"44","author":"Gandhi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020081003472495600_CIT0042","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/cis289","article-title":"Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus","volume":"54","author":"Hull","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/3\/ofz055\/33590387\/ofz055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/3\/ofz055\/33590387\/ofz055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T07:49:25Z","timestamp":1597045765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz055\/5318372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz055","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,2,13]]},"article-number":"ofz055"}}